RÉSUMÉ
Photodynamic therapy (PDT) is a new oncotherapy method. Photosensitizer and matched-light are the key elements of PDT. As a next generation photosensitizers of high purity, sinoporphyrin sodium (DVDMS) has the characteristics of clear structure and high content, low effective dose, short time avoiding light after treatment and good safety. Due to the discovery of ultrasonic sensitivity of DVDMS, great progresses have been made on the research and application of DVDMS-mediated sonodynamic therapy. Research suggests that DVDMS has potentials to be used for anti-tumor, anti-bacterial, treatment of psoriasis, development of therapeutic diagnostic reagents and so on. This review sums up the anti-tumor activities and mechanisms of DVDMS.
RÉSUMÉ
Objective To establish a HPLC method for the assay of sinoporphyrin sodium (DVDMS) in tumor-bearing mouse plasma and to study its pharmacokinetics .Methods The column was Waters XBridge C18 (3 .0 mm × 100 mm ,3 .5μm) . Gradient elution was applied with mobile phase A as the mixture of acetonitrile-methanol (20:80) and B as the aqueous solu-tion of 1％ acetic acid and 0 .1％ triethylamine at flow rate 0 .7 ml/min .The detection wavelength was 380 nm .DVDMS was administrated to tumor-bearing mice by tail vein injection .The blood samples were collected at designated time and centrifuged for plasma .DVDMS in plasma samples were extracted by protein precipitation and analyzed by the HPLC method mentioned a-bove .Pharmacokinetic parameters were calculated by DAS 2 .0 with statistical moment analysis .Results DVDMS showed good linearity within the ranges of 70 .8-14160 ng/ml (r=0 .9998) .The main pharmacokinetic parameters were calculated as follows :cmax = (24127 .59 ± 1415 .23) ng/ml ,tmax =0 .083 h ,t1/2 = (9 .59 ± 1 .25) h ,MRT0-∞ = (11 .77 ± 1 .73) h ,AUC0-∞ =(34775 .83 ± 6185 .43) h · ng/ml .Conclusion This HPLC method is sensitive ,rapid and accurate ,which can be used for a-nalysis and research of DVDMS in plasma samples of tumor-bearing mice .
RÉSUMÉ
Objective To fabricate DVDMS-Mn-LPs and evaluate its potential on fluorescence mo-lecular imaging, MRI and sonodynamic therapy ( SDT) . Methods DVDMS was used to chelate with Mn2+, and then encapsulated into nanoliposomes by a typical thin-film rehydration method to fabricate DVDMS-Mn-LPs. The particle morphology, average diameter, zeta potential, encapsulation efficiencies and Mn2+content were determined. Fluorescence molecular imaging was performed on different concentrations of DVDMS-Mn-LPs (0, 40, 80, 120, 160 μg/ml) with the small animal fluorescence imaging system. T1WI was per-formed with 3.0 T MR. The SDT effect of DVDMS-Mn-LPs was verified by CCK8 assay among the following groups:control group, ultrasound group ( experimental group 1, EG1) , DVDMS-Mn-LPs group ( EG2) and DVDMS-Mn-LPs + ultrasound group ( EG3) . One-way analysis of variance and the least significant differ-ence t test were used to analyze the data. Results DVDMS-Mn-LPs exhibited a well-defined spherical mor-phology and homogeneous distribution. The encapsulation efficiency was (65.56±1.47)%. ICP-AES meas-urement revealed that the chelation of Mn2+ with DVDMS occurred at a molar ratio of 1. 6:1. The fluores-cence intensities progressively increased with the elevated concentrations of DVDMS-Mn-LPs. The r1 value for DVDMS-Mn-LPs was 23.74 mmol·L-1·s-1. The cell viabilities of EG3 was (54.82±8.55)%, which were significantly lower than those of EG2 and EG1 ((86.54±2.67)% and (83.76±6.48)%;F=6011, t values: -8.35, -9.15, all P<0.001). Conclusion DVDMS-Mn-LPs is successfully fabricated and has good potential on fluorescence molecular imaging, MRI and SDT, which provides a promising imaging-guided modality for glioma treatment in vivo.